Differentiated thyroid cancer and selenium supplements for protection of salivary glands from 131I treatment

被引：0
|
作者：
Mazokopakis, Elias E. [1 ]
机构：
[1] Naval Hosp Crete, Dept Internal Med, Khania 73200, Crete, Greece
来源：
HELLENIC JOURNAL OF NUCLEAR MEDICINE | 2018年 / 21卷 / 01期
关键词：
HASHIMOTOS-THYROIDITIS; MANAGEMENT;
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：83 / 84
页数：2
相关论文
共 50 条
  • [21] Ultrasonography Echotexture as a surrogate for Sialadenitis secondary to 131I Radioiodine Therapy for differentiated Thyroid Cancer: a review and metaanalysis
    Simoes Lima, Graziele Aparecida
    Mendoza Lopez, Rossana Veronica
    Ozorio, Gislaine Aparecida
    Costa de Freitas, Ricardo Miguel
    Willegaignon, Jose
    Sapienza, Marcelo Tatit
    Chammas, Maria Christina
    Coura-Filho, George Barberio
    CLINICS, 2020, 75
  • [22] 131I SPECT/CT in the Follow-Up of Patients With Differentiated Thyroid Carcinoma
    Menges, Mareen
    Uder, Michael
    Kuwert, Torsten
    Schmidt, Daniela
    CLINICAL NUCLEAR MEDICINE, 2012, 37 (06) : 555 - 560
  • [23] Esophageal Metastasis From Papillary Thyroid Cancer Diagnosis by 131I SPECT/CT
    Wisotzki, Christian
    Friese, Michael
    Ehresmann, Joerg
    Derlin, Thorsten
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (01) : E73 - E74
  • [24] Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients
    Dekker, Bernadette L.
    Links, Mirthe H.
    Kobold, Anneke C. Muller
    Swart-Busscher, Linda G.
    Kars, Marleen
    Bons, Judith A. P.
    Brouwers, Adrienne H.
    Links, Thera P.
    Van der Horst-Schrivers, Anouk N. A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02): : E604 - E611
  • [25] Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective
    Higashi, Tatsuya
    Kudo, Takashi
    Kinuya, Seigo
    ANNALS OF NUCLEAR MEDICINE, 2012, 26 (02) : 99 - 112
  • [26] Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without 131I Ablation
    Matrone, Antonio
    Latrofa, Francesco
    Torregrossa, Liborio
    Piaggi, Paolo
    Gambale, Carla
    Faranda, Alessio
    Ricci, Debora
    Agate, Laura
    Molinaro, Eleonora
    Basolo, Fulvio
    Vitti, Paolo
    Elisei, Rossella
    THYROID, 2018, 28 (07) : 871 - 879
  • [27] TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer
    Ju, Nianting
    Hou, Liying
    Song, Hongjun
    Qiu, Zhongling
    Wang, Yang
    Sun, Zhenkui
    Luo, Quanyong
    Shen, Chentian
    EUROPEAN THYROID JOURNAL, 2023, 12 (04)
  • [28] Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131I
    Zhang, Xin-Yun
    Song, Hong-Jun
    Qiu, Zhong-Ling
    Shen, Chen-Tian
    Chen, Xiao-Yue
    Sun, Zhen-Kui
    Wei, Wei-Jun
    Zhang, Guo-Qiang
    Luo, Quan-Yong
    ENDOCRINE, 2018, 62 (01) : 149 - 158
  • [29] Two or three weeks of thyroid hormone withdrawal before initial 131I therapy for patients with differentiated thyroid carcinoma?
    Wang, Yueqi
    Huang, Shuhui
    Huang, Rui
    BMC CANCER, 2025, 25 (01)
  • [30] Impact of 131I SPECT/Spiral CT on Nodal Staging of Differentiated Thyroid Carcinoma at the First Radioablation
    Schmidt, Daniela
    Szikszai, Attila
    Linke, Rainer
    Bautz, Werner
    Kuwert, Torsten
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (01) : 18 - 23
12345